Last reviewed · How we verify
Anastrozole and goserelin
Aromatase inhibitor
Aromatase inhibitor Used for Breast cancer.
At a glance
| Generic name | Anastrozole and goserelin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Aromatase inhibitor and GnRH agonist |
| Target | Aromatase and GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Anastrozole inhibits the enzyme aromatase, which is involved in the biosynthesis of estrogen. Goserelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses the production of gonadotropins, leading to a decrease in estrogen levels.
Approved indications
- Breast cancer
Common side effects
- Hot flashes
- Vaginal dryness
- Osteoporosis
Key clinical trials
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (PHASE3)
- Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (PHASE3)
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (PHASE3)
- Roll-over Study to Allow Continued Access to Ribociclib (PHASE4)
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (PHASE2)
- Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (PHASE2)
- Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PHASE2)
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anastrozole and goserelin CI brief — competitive landscape report
- Anastrozole and goserelin updates RSS · CI watch RSS
- AstraZeneca portfolio CI